Success Metrics

Clinical Success Rate
71.4%

Based on 10 completed trials

Completion Rate
71%(10/14)
Active Trials
3(14%)
Results Posted
120%(12 trials)
Terminated
4(19%)

Phase Distribution

Ph phase_3
11
52%
Ph phase_1
3
14%
Ph phase_2
5
24%
Ph phase_4
1
5%

Phase Distribution

3

Early Stage

5

Mid Stage

12

Late Stage

Phase Distribution20 total trials
Phase 1Safety & dosage
3(15.0%)
Phase 2Efficacy & side effects
5(25.0%)
Phase 3Large-scale testing
11(55.0%)
Phase 4Post-market surveillance
1(5.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.4%

10 of 14 finished

Non-Completion Rate

28.6%

4 ended early

Currently Active

3

trials recruiting

Total Trials

21

all time

Status Distribution
Active(6)
Completed(10)
Terminated(4)
Other(1)

Detailed Status

Completed10
Terminated4
Recruiting2
Not yet recruiting2
unknown1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
21
Active
3
Success Rate
71.4%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (15.0%)
Phase 25 (25.0%)
Phase 311 (55.0%)
Phase 41 (5.0%)

Trials by Status

unknown15%
recruiting210%
enrolling_by_invitation15%
active_not_recruiting15%
completed1048%
terminated419%
not_yet_recruiting210%

Recent Activity

Clinical Trials (21)

Showing 20 of 21 trialsScroll for more
NCT05063162Phase 3

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)

Active Not Recruiting
NCT06149559Phase 2

A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis

Recruiting
NCT06720714Phase 1

A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women

Completed
NCT06540144Phase 3

An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

Enrolling By Invitation
NCT07246564Phase 4

Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

Recruiting
NCT07463521Phase 3

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

Not Yet Recruiting
NCT07465289Phase 3

A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

Not Yet Recruiting
NCT03971422Phase 3

A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

Completed
NCT05681715Phase 3

A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

Completed
NCT05643794Phase 2

A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome

Completed
NCT04875975Phase 2

A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

Terminated
NCT04650854Phase 3

A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis

Completed
NCT04200456Phase 3

A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

Terminated
NCT04828343Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants

Completed
NCT04596995Phase 3

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

Terminated
NCT05014724

CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)

Unknown
NCT04124965Phase 3

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

Completed
NCT04224688Phase 3

A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

Terminated
NCT03861481Phase 2

A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Completed
NCT04051944Phase 2

A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Completed

Drug Details

Intervention Type
DRUG
Total Trials
21